Nanoparticle Warfarin + Focused Ultrasound: Hossein Mehrad on Next-Gen Thrombolysis
Hossein Mehrad, Managing Director of Tajhiz Teb Fannavar Parto Company, Director of Mehrad Research Lab, posted on LinkedIn:
”This article investigates the effects of administering Intravenous Lipid-Based Encapsulated Warfarin Nanoparticles on the enhancement of cerebral clot dissolution using Pulsed Low-Level Focused Ultrasound (PLIFU).
The central concept is that combining a Targeted Anticoagulant Delivery system with focused ultrasound stimulation can accelerate and improve the efficiency of Cerebral Thrombolysis. The lipid nanoparticles provide a stable matrix that encapsulates Warfarin Molecules at the nanoscale, preventing their premature degradation in the bloodstream. This nanostructure improves the Pharmacokinetics and Biodistribution of the drug within brain tissue, which naturally shows limited permeability.
The presence of the Lipid Shell enables more effective interaction with Cell Membranes and the Cerebral Microvasculature. Once in circulation, the nanoparticles are exposed to Low-Frequency Pulsed Ultrasound directed at the occluded region. These acoustic waves generate Micro-Mechanical Oscillations and Stable Cavitation around the clot, increasing Tissue Permeability and enhancing Clot Penetration of the nanoparticles. Mechanical stimulation from PLIFU also induces Fibrin Network Disruption, making the clot more responsive to therapeutic activity.
Encapsulated warfarin is released within the clot according to Controlled Release Kinetics, which boosts Targeted Bioavailability and avoids fluctuations in systemic drug concentration. Warfarin further inhibits the Vitamin K-Dependent Coagulation Pathway, preventing clot reinforcement. The integration of chemical inhibition and mechanical ultrasound stimulation results in a significant Synergistic Effect.
Because PLIFU operates at a very low intensity, it minimizes Thermal Damage to cerebral tissue. Overall therapeutic performance depends on Nanoparticle Delivery Efficiency and Acoustic Pressure Amplitude. Animal studies demonstrate faster and more complete clot degradation when nanowarfarin is combined with PLIFU, and Neuroimaging Analysis confirms improved Reperfusion. Effective system design requires precise control of Nanoparticle Size Distribution and Ultrasound Parameters.
This combined strategy represents a promising approach in Non-Invasive Thrombolytic Therapy, with evidence suggesting improved safety, reduced drug dosage, and enhanced clinical outcomes.”
Keep up with Hemostasis Today.
-
Mar 12, 2026, 20:44Honoring Marion Stolte’s Lasting Impact on the Bleeding Disorders Community – WFH
-
Mar 12, 2026, 20:37Paul Riley: Is Thrombin Generation Assay Ready for Prime Time?
-
Mar 12, 2026, 20:28Rob Maloney: Building Visibility for Bleeding Disorders in Rural Georgia
-
Mar 12, 2026, 20:19Akshat Jain: Validating Oral Pain Medication Use as a Global Marker in Sickle Cell Disease
-
Mar 12, 2026, 20:13Michael Makris: Early Clinical Results of AAV8-BDD FVIII Gene Therapy in Hemophilia A
-
Mar 12, 2026, 20:02Wolfgang Miesbach: From Heparin to Vaccines – The Expanding Biology of Anti-PF4 Immunothrombosis
-
Mar 12, 2026, 19:56Christophe Dubois: Celebrating Nicolas Gendron’s HDR Defense and Future in Hemostasis
-
Mar 12, 2026, 17:06Caitlin Raymond: Managing Crigler–Najjar Syndrome Type 1 Crisis Without a Standard TPE Protocol
-
Mar 12, 2026, 17:03Jan Sloves: Insights on Comprehensive Venous Duplex Imaging at VEITH Symposium 2025